New Insights into LINC00346 and its Role in Disease

Lü, Juan; Xiao, Zhaoying; Xu, Mengqiu; Li, Lanjuan

doi:10.3389/fcell.2021.819785

Cited by 3 publications

(2 citation statements)

References 116 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LINC00346, located on chromosome 13q34, has shown abnormal expression in various diseases including NPC. Its aberrant expression significantly correlates with tumor proliferation, invasion, and drug resistance, establishing it as a potential biomarker for disease diagnosis and treatment ( 40 ). There is no doubt that chemotherapy sensitivity of malignant tumor cells is closely related to cell proliferation and apoptosis ( 41 ).…”

Section: Role Of Incrna In Npc Chemotherapy Resistancementioning

confidence: 99%

Role of long non-coding RNA in chemoradiotherapy resistance of nasopharyngeal carcinoma

Yang,

Yuan,

Tang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the nasopharyngeal epithelial cells. Common treatment methods for NPC include radiotherapy, chemotherapy, and surgical intervention. Despite these approaches, the prognosis for NPC remains poor due to treatment resistance and recurrence. Hence, there is a crucial need for more comprehensive research into the mechanisms underlying treatment resistance in NPC. Long non coding RNAs (LncRNAs) are elongated RNA molecules that do not encode proteins. They paly significant roles in various biological processes within tumors, such as chemotherapy resistance, radiation resistance, and tumor recurrence. Recent studies have increasingly unveiled the mechanisms through which LncRNAs contribute to treatment resistance in NPC. Consequently, LncRNAs hold promise as potential biomarkers and therapeutic targets for diagnosing NPC. This review provides an overview of the role of LncRNAs in NPC treatment resistance and explores their potential as therapeutic targets for managing NPC.

show abstract

Section: Role Of Incrna In Npc Chemotherapy Resistancementioning

confidence: 99%

Role of long non-coding RNA in chemoradiotherapy resistance of nasopharyngeal carcinoma

Yang,

Yuan,

Tang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These lncRNAs have been shown to influence signaling pathways involved in the progression of cancer. For instance, the lncRNA LINC00346 promotes tumor progression by regulating the PI3K/AKT signaling pathway, leading to enhanced cell proliferation, migration, invasion, apoptosis, and metastasis [ 149 ]. Urothelial carcinoma association 1 (UCA1) affects the proliferation and invasive characteristics of bladder carcinoma cells through the PI3-K-dependent pathway and under the influence of CREB [ 97 , 105 ].…”

Section: Role Of Long Noncoding Rnas (Lncrnas) In Blcamentioning

confidence: 99%

Epigenetic and Immunological Features of Bladder Cancer

Gilyazova

Enikeeva

Rafikova

et al. 2023

IJMS

View full text Add to dashboard Cite

Bladder cancer (BLCA) is one of the most common types of malignant tumors of the urogenital system in adults. Globally, the incidence of BLCA is more than 500,000 new cases worldwide annually, and every year, the number of registered cases of BLCA increases noticeably. Currently, the diagnosis of BLCA is based on cystoscopy and cytological examination of urine and additional laboratory and instrumental studies. However, cystoscopy is an invasive study, and voided urine cytology has a low level of sensitivity, so there is a clear need to develop more reliable markers and test systems for detecting the disease with high sensitivity and specificity. Human body fluids (urine, serum, and plasma) are known to contain significant amounts of tumorigenic nucleic acids, circulating immune cells and proinflammatory mediators that can serve as noninvasive biomarkers, particularly useful for early cancer detection, follow-up of patients, and personalization of their treatment. The review describes the most significant advances in epigenetics of BLCA.

show abstract

Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling

Błasiak

Chojnacki

Pawłowska

et al. 2022

IJMS

View full text Add to dashboard Cite

Dietary vitamin D3 has attracted wide interest as a natural compound for breast cancer prevention and therapy, supported by in vitro and animal studies. The exact mechanism of such action of vitamin D3 is unknown and may include several independent or partly dependent pathways. The active metabolite of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D, calcitriol), binds to the vitamin D receptor (VDR) and induces its translocation to the nucleus, where it transactivates a myriad of genes. Vitamin D3 is involved in the maintenance of a normal epigenetic profile whose disturbance may contribute to breast cancer. In general, the protective effect of vitamin D3 against breast cancer is underlined by inhibition of proliferation and migration, stimulation of differentiation and apoptosis, and inhibition of epithelial/mesenchymal transition in breast cells. Vitamin D3 may also inhibit the transformation of normal mammary progenitors into breast cancer stem cells that initiate and sustain the growth of breast tumors. As long noncoding RNAs (lncRNAs) play an important role in breast cancer pathogenesis, and the specific mechanisms underlying this role are poorly understood, we provided several arguments that vitamin D3/VDR may induce protective effects in breast cancer through modulation of lncRNAs that are important for breast cancer pathogenesis. The main lncRNAs candidates to mediate the protective effect of vitamin D3 in breast cancer are lncBCAS1-4_1, AFAP1 antisense RNA 1 (AFAP1-AS1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), long intergenic non-protein-coding RNA 511 (LINC00511), LINC00346, small nucleolar RNA host gene 6 (SNHG6), and SNHG16, but there is a rationale to explore several other lncRNAs.

show abstract

New Insights into LINC00346 and its Role in Disease

Cited by 3 publications

References 116 publications

Role of long non-coding RNA in chemoradiotherapy resistance of nasopharyngeal carcinoma

Role of long non-coding RNA in chemoradiotherapy resistance of nasopharyngeal carcinoma

Epigenetic and Immunological Features of Bladder Cancer

Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling

Contact Info

Product

Resources

About